查看文章

The current recommendations for the treatment of LN consider as the standard of care (SoC) the use of MMF or CYC. Considering the expanding evidence for using calcineurin inhibitors (CNI) in patients with LN, we aimed to summarize and assess the efficacy and safety of CNI compared to the current SoC for treating patients with LN.

We comprehensively searched MEDLINE, EMBASE, CENTRAL, and Scopus from each database’s inception to January 19, 2023. Studies were eligible if they included (P) patients with biopsy-proven LN, (I) compared CNI (voclosporin, tacrolimus, and CSA) alone or in combination with other immunosuppressors (IST) against (C) the SoC (MMF or CYC), (O) for efficacy (complete and partial renal response [CR and PR, respectively]) and safety (death, infections, gastrointestinal adverse effects [GIAE], cytopenias). Exclusion criteria were patients with SLE without …